Roger D. Klein, MD JD is Chief Medical Officer of OmniSeq, a cancer genomic profiling company. He is an expert with the Federalist Society Regulatory Transparency Project’s FDA & Health Working Group, a former HHS Advisor to FDA, CMS and CDC, and a leading authority on public policies related to the implementation of precision medicine. A physician and an attorney, Dr. Klein was previously Medical Director of Molecular Oncology at Cleveland Clinic, and has served in leadership roles in many cancer-related professional society committees, including past Chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. Notably, Dr. Klein was an Expert and key spokesperson for AMP in its landmark lawsuit in which the U.S. Supreme Court invalidated patents on “the breast cancer genes.” He is a frequent guest on national radio and television programs and a regular opinion contributor to The Hill, the Daily Caller, Real Clear Health, Wall Street Journal, New York Post, City Journal, Investor’s Business Daily, and other periodicals. Dr. Klein completed post-graduate medical training at Yale Medical School and obtained his J.D. from Yale Law School.